Serum biologic markers as predictors of disease progression in osteoarthritis of the knee

Georges, Claire; Vigneron, Hélène; Ayral, X.; Listrat, V.; Ravaud, Philippe; Dougados, Maxime; Sharif, Mohammed; Dieppe, Paul; Saxne, Tore

doi:10.1002/art.1780400333

Cited by 28 publications

(19 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as previously noted 20 , the large variability in COMP concentrations between individuals limits its sensitivity for detecting small changes in disease state over time. Hence, it is not surprising that the results of this study were consistent with other studies 14,15,17,19 where individual baseline pre-activity concentrations of COMP were not correlated with cartilage thickness changes over a 5-year time period. However, examining COMP levels in response to a mechanical stimulus appears to normalize the response of COMP to individual variations in resting levels and produces a short-term change in COMP concentration that is significantly associated with long-term morphological changes in cartilage.…”

Section: Discussionsupporting

confidence: 88%

A relationship between mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in cartilage thickness after 5 years

Erhart‐Hledik

Favre

Asay

et al. 2012

Osteoarthritis and Cartilage

122

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

A relationship between mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in cartilage thickness after 5 years

Erhart‐Hledik

Favre

Asay

et al. 2012

Osteoarthritis and Cartilage

122

View full text Add to dashboard Cite

show abstract

“…Predictive values of serum levels of C-reactive protein (43), COMP (44,45), and hyaluronic acid (46) have been found in some studies, but not in all (47). However, molecular markers investigated in these studies were not specific to joint tissue (6), and none of the studies evaluated the metabolism of type II collagen, the most abundant protein of cartilage matrix.…”

Section: Discussionmentioning

confidence: 99%

Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis

Garnero¹,

Ayral²,

Rousseau³

et al. 2002

Arthritis & Rheumatism

Self Cite

264

200

View full text Add to dashboard Cite

Objective. The hallmark of osteoarthritis (OA) is the loss of articular cartilage. This loss arises from an imbalance between cartilage synthesis and cartilage degradation over a variable period of time. The aims of this study were to investigate the rates of these processes in patients with knee OA using two new molecular markers and to investigate whether the combined use of these markers could predict the progression of joint damage evaluated by both radiography and arthroscopy of the joints during a period of 1 year.Methods. Seventy-five patients with medial knee OA (51 women, 24 men; mean ؎ SD age 63 ؎ 8 years, mean ؎ SD disease duration 4.8 ؎ 5.2 years) were studied prospectively. At baseline, we measured serum levels of N-propeptide of type IIA procollagen (PIIANP) and urinary excretion of C-terminal crosslinking telopeptide of type II collagen (CTX-II) as markers of type II collagen synthesis and degradation, respectively. Joint space width (JSW) on radiography and medial chondropathy at arthroscopy (assessed using a 100-mm visual analog scale [VAS]) were measured in all patients at baseline and in 52 patients at 1 year. Progression of joint destruction was defined as a decrease of >0.5 mm in JSW on radiography and as increased chondropathy (an increase in the VAS score of >8.0 units) between the baseline and 1-year evaluations.Results. At baseline, compared with 58 healthy age-and sex-matched controls, patients with knee OA had decreased serum levels of PIIANP (20 ng/ml versus 29 ng/ml; P < 0.001) and increased urinary excretion of CTX-II (618 ng/mmole creatinine [Cr] versus 367 ng/ mmole Cr; P < 0.001). The highest discrimination between OA patients and controls was obtained by combining PIIANP and CTX-II in an uncoupling index (Z score CTX-II ؊ Z score PIIANP), which yielded a mean Z score of 2.9 (P < 0.0001). Increased baseline values in the uncoupling index were associated with greater progression of joint damage evaluated either by changes in JSW (r ‫؍‬ ؊0.46, P ‫؍‬ 0.0016) or by VAS score (r ‫؍‬ 0.36, P ‫؍‬ 0.014). Patients with both low levels of PIIANP (less than or equal to the mean ؊ 1 SD in controls) and high levels of CTX-II (greater than or equal to the mean ؉ 1 SD in controls) had an 8-fold more rapid progression of joint damage than other patients (P ‫؍‬ 0.012 and P < 0.0001 as assessed by radiography and arthroscopy, respectively) and had relative risks of progression of 2.9 (95% confidence interval [95% CI] 0.80-11.1) and 9.3 (95% CI 2.2-39) by radiography and arthroscopy, respectively.Conclusion. Patients with knee OA are characterized by an uncoupling of type II collagen synthesis and degradation which can be detected by assays for serum PIIANP and urinary CTX-II. The combination of these two new markers could be useful for identifying knee OA patients at high risk for rapid progression of joint damage.

show abstract

“…54,55) It also has been reported that serum HA level was associated with the presence of radiographic knee OA. [56][57][58][59] It has been reported normal human the HA level in the ranged from 53.9 to 55.2 ng/mL. 60) In the present study, we used serum COMP and HA levels to evaluate these effects during CS therapy.…”

Section: )mentioning

confidence: 94%

Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan

Morita

Yamada

Date

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, doubleblind, dose-comparison study. Patients with painful, Kellgren-Lawrence grade 2-3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne's index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne's index ≥8 or <8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne's index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months' therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.Key words chondroitin sulfate; pain-management; clinical trial; randomized controlled trial Osteoarthritis (OA) is the most common form of arthritis and is a major cause of morbidity, activity limitation, physical disability, excess health care utilization, and reduced healthrelated QOL, especially in people aged 65 years and older.

show abstract

Serum biologic markers as predictors of disease progression in osteoarthritis of the knee

Cited by 28 publications

References 3 publications

A relationship between mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in cartilage thickness after 5 years

A relationship between mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in cartilage thickness after 5 years

Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis

Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan

Contact Info

Product

Resources

About